Want to join the conversation?
$URI narrowed its 2016 total revenue outlook to $5.65-5.75Bil from prior range of $5.6-5.8Bil and its adjusted EBITDA forecast to $2.70-2.75Bil from $2.65-2.75Bil. $URI lifted net cash provided by operating activities guidance to $1.7-1.8Bil from prior range of $1.6-1.7Bil and free cash flow estimate to $1-1.1Bil from $0.9-1Bil.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.